AKT1 and neoplasm: In addition to nucleic acid drugs, small molecule drugs such as Bindarit can reduce the synthesis of CCL2 by inhibiting AKT and NF-κB pathways, showing potential inhibitory effects on tumor progression and metastasis (226).